BioSpace News Archive

Thermo Fisher Scientific Inc. hosted its 2023 Investor Day today and provided an in-depth review of the Company’s proven growth strategy and its industry-leading businesses.

Stryker, one of the world’s leading medical technology companies, announced that Early Product Surveillance cases utilizing its Q Guidance System with Cranial Guidance Software are underway.

Mental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S.

Jaguar Health, Inc. today announced that Stacey Tinianov, MPH, a Board Certified Patient Advocate, has joined the Company’s Scientific Advisory Board (SAB).

Palisade Bio, Inc. today provided a clinical program update for its ead product candidate, LB1148, a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage.

AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the recipients of the 2023 AACC and AACC Academy Awards.

Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced positive and statistically significant top-line results from the randomized controlled NASAR clinical trial evaluating its Bentrio nasal spray in patients with seasonal allergic rhinitis (SAR).

INmune Bio Inc. (NASDAQ: INMB) announces that Mark Lowdell, Ph.D., INmune Bio’s CSO, will be giving the opening plenary lecture of the Presidential Symposium at the International Society of Cell and Gene Therapy (ISCT) in Paris, France on May 31st.

vTv Therapeutics Inc. announced that the United States Patent and Trademark Office recently issued a patent to Cantex Pharmaceuticals, Inc. that covers claims related to the use of azeliragon as a potential treatment of glioblastoma multiforme.

Aerami Therapeutics (“Aerami”) today announced results from studies of AER-901 (inhaled imatinib) that support progression into a Phase 2 clinical trial in both pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).